PD-L1 Clones and Their Relevance in Glioblastoma, IDH-Wildtype: A Comparative Analysis
| Autoři | |
|---|---|
| Rok publikování | 2025 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Bratislava Medical Journal |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://link.springer.com/article/10.1007/s44411-025-00245-y |
| Doi | http://dx.doi.org/10.1007/s44411-025-00245-y |
| Klíčová slova | Immunotherapy; Glioblastoma; PD-L1; SP263; 22C3; Biomarker |
| Přiložené soubory | |
| Popis | Glioblastoma, IDH-wildtype (GBM), is the most common primary brain cancer and is associated with a poor prognosis. Anti-PD-L1 immune checkpoint inhibitors have shown promising results in other solid tumors, prompting studies evaluating their potential in GBM. Accurately determining programmed death-ligand 1 (PD-L1) expression, using different antibody clones, is essential for assessing the potential efficacy of immunotherapy in GBM patients. However, the variability in immunohistochemical expression of different PD-L1 clones in GBM has not been tested. This study aims to assess and compare PD-L1 expression using two antibody clones SP263 and 22C3 in a retrospective GBM cohort. PD-L1 testing yielded spatial variability within the same tumor sample and significant discordance between the tested PD-L1 assays with the SP263 clone consistently detecting higher PD-L1 positivity. Overall, 46.5% of GBM cases were PD-L1 positive (? 5%) with SP263, compared to 32.6% with 22C3. The inter-clone kappa agreement reached 0.71. Positive cases (? 5%) were 53.8% and 38.5% in the unmethylated MGMT GBM subgroup with SP263 and 22C3 respectively, while 35.3% or 23.5% in the methylated MGMT GBMs. Our findings underscore that commonly used PD-L1 assays yield discordant results, highlighting the need to establish a gold standard for PD-L1 testing as a predictive biomarker. |
| Související projekty: |